| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Third National Report on the implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
109117
Status
Published
Date of creation
2015-10-31 15:13 UTC (djibril.dayamba@yahoo.fr)
Date of publication
2015-10-31 15:13 UTC (djibril.dayamba@yahoo.fr)

This document is also available in the following languages:
Origin of report
1. Country
  • Burkina Faso
Contact officer for report
Coordinates
Prof Chantal Yvette ZOUNGRANA / KABORE
Director General
Agence nationale de biosécurité (ANB)
01 BP 5933 Ouagadougou 01, Burkina Faso
Ouagadougou, Kadiogo
Burkina Faso, 01 BP 5933
Phone:+226 25378854
Email:cykabore@yahoo.fr
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
FR
Agence nationale de biosécurité, comité scientifique national de biosécurité, observatoire national de biosécurité, différents ministères (recherche, enseignement, santé, environnement, agriculture, justice, ressources animales, commerce), sociétés cotonières, associations de producteurs, de femmes, communicateurs, société civile, personnes ressources
Submission
10. Date of submission
2015-10-31
11. Time period covered by this report
Start date
2011-10-31
11. Time period covered by this report
End date
2015-10-31
Party to the Cartagena Protocol on Biosafety
Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
14. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
This question is relevant to indicators 1.1.1, 2.1.1, 2.1.2, and 3.1.2 of the Strategic Plan
  • A domestic regulatory framework is fully in place
15. If you indicated that a national biosafety framework exists in the above question, when did it become operational?
This question is relevant to the indicator 1.1.1 of the Strategic Plan
  • 2006
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety laws
  • One or more national biosafety regulations
  • Other laws, regulations or guidelines that indirectly apply to biosafety
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • Yes
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • Yes
19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?
  • More than 10
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Partially
21. Here you may provide further details on the implementation of Article 2 in your country
FR
Mesures administratives :
cadre national de biosécurité en 2004; autorité nationale compétente: Agence nationale de biosécurité (ANB) en 2005; acquisition d'une autonomie administrative et de gestion en 2015; Comité scientifique national de biosécurité (CSNB) en 2006; Observatoire national de biosécurité (ONB) en 2008.
Mesures juridiques :
règles nationales en matière de sécurité en biotechnologies en 2004; loi n°005-2006/AN portant régime de sécurité en matière de biotechnologie au Burkina Faso; loi n°064-2012/AN portant régime de sécurité en matière de biotechnologie  Décret n°254-2015/PRES-TRANS/PM/MRSI/MEFdu 17/3/2015 portant fixation des modalités financières pour l'évaluation des demandes d'utilisation et les inspections des organismes génétiquementmodifiés; Décret n°219-2015/PRES-TRANS/PM/MRSI/MERH/MESS/MARHSA/MICA,du 5/3/2015 portant conditions de transport et d'exportation / importation des organismes génétiquement modifiés; Décret n°253-2015/PRES-TRANS/PM/MRSI/MEF du 7/3/2015 portant attributions, composition, organisation et fonctionnement du Comité Scientifique National de Biosécurité (CSNB); Décret n°225-2015/PRES-TRANS/PM/ MRSI/MERH/MARHASA/MS/MICA du 5/3/2015 portant conditions de  dissémination ou de mise sur le marché des organismes génétiquement modifiés. Décret n°2015/PRES-TRANS/PM/MRSI/MESS/MERH  portant évaluation des risques biotechnologiques Décret n°216-2015/PRES-TRANS/PM/MRSI/MARHASA/MRA/MS du 5/3/2015 portant procédures d'essai des organismes génétiquement modifiés en milieu ouvert. Décret n°217-2015/PRES-TRANS/PM/MRSI/MERH/MS/MESS/MARHASA/MRA/MICA du 5/3/2015 portant conditions de destruction des organismes  génétiquement modifiés présentant des risques avérés pour la santé humaine, animale et/ou l'environnement; Décret n°215-2015/PRES-TRANS/PM/MRSI/MERH/MRA/MESS/MS du 5/3/2015 portant détermination des risques et modalités de confinement des travaux de  biotechnologie ;Décret n°444-2015/PRES-TRANS/PM/MEF/MRSI portant attributions, composition, organisation et fonctionnement de l'Observatoire national de biosécurité; Décret n°2015/PRES/PM/MEF/MRSI portant érection de l'Agence Nationale de Biosécurité (ANB) en établissement public de l'Etat à caractère scientifique, culturel et technique
Loi 003-2011/AN du 5/01/2011 portant code forestier au Burkina Faso;
Loi n°06-2013/AN du  portant code de l'environnement au Burkina Faso
Loi 008-2014/AN du 8/04/2014 portant loi d'orientation sur le développement durable;
Article 5 - Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • Yes
23. If you answered Yes to question 22, has this information been submitted to the BCH?
  • No
24. Here you may provide further details on the implementation of Article 5 in your country:
FR
Il n'y a pas de traitement spécifique pour les produits pharmaceutiques qui sont des OGM; ils sont traités de la même façon que tout autre produit pharmaceutique
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
This question is relevant to indicator 1.8.1 of the Strategic Plan
  • Yes
26. Does your country regulate the contained use of LMOs?
This question is relevant to indicators 1.1.2 and 1.8.2 of the Strategic Plan
  • Yes
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
  • Yes
28. Here you may provide further details on the implementation of Article 6 in your country:
FR
Le transit des OGM suit la même procédure que l'importation et cela est spécifié dans la loi N°064-2012/AN du 20/12/2012 portant régime de sécurité en matière de biotechnologie.
Le milieu confiné est aussi réglementé par la même loi
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol OR a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
This question is relevant to indicators 1.1.2 and 3.1.4 of the Strategic Plan
  • Yes
30. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Yes
31. If you answered Yes to question 30, does the mechanism also apply to cases of intentional introduction of LMOs into the environment that were not subject to transboundary movement?
  • Yes
32. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • Yes
33. Has your country established legal requirements for the accuracy of information contained in the notification?
  • Yes
34. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
This question is relevant to indicator 1.1.4 of the Strategic Plan
  • Yes
35. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
This question is relevant to indicator 1.1.5 of the Strategic Plan
  • Yes
36. If you answered Yes to question 35, how many LMOs has your country approved to date for import for intentional introduction into the environment?
  • Less than 5
37. If you answered Yes to question 35, how many LMOs, not imported, has your country approved to date for intentional introduction into the environment?
  • None
38. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • More than 10
39. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • More than 10
40. With reference to the decisions taken on intentional transboundary movements of LMOs for intentional introduction into the environment, has your country received a notification from the Party(ies) of export or from the exporter(s) prior to the transboundary movement?
  • Yes
41. Did the notifications contain complete information (at a minimum the information specified in Annex I of the Cartagena Protocol on Biosafety)?
  • Yes
42. Has your country acknowledged receipt of the notifications to the notifier within ninety days of receipt?
  • Yes
43. Has your country informed the notifier(s) and the BCH of its decision(s)?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • In some cases only
44. What percentage of your country’s decisions fall into the following categories?
  • Approval of the import/use of the LMO(s) with conditions
100%
  • Approval of the import/use of the LMO(s) without conditions
0%
  • Inform the notifier that the period for communicating the decision has been extended
0%
  • Prohibition of the import/use of the LMO(s)
0%
  • Request for additional relevant information
0%
45. In cases where your country approved an import with conditions or prohibited an import, did it provide reasons on which its decisions were based to the notifier and the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • In some cases only the notifier
46. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment
FR
La réglementation du Burkina Faso précise que toute activité relative à l'utilisation en milieu confiné ou en milieu ouvert, à la dissémination, à la mise sur le marché et aux mouvements transfrontières incluant le transit d'organismes génétiquement modifiés fait l'objet d'un accord préalable en connaissance de cause.
La notification est faite conformémement aux dispositions de l'article 8 du protocole.
L'accusé de reception de la notification est adressé par écrit à l'auteur de la notification. Il indique la date de réception de la notification. L'accusé de reception n'est délivré que si la notification contient à première vue toutes les réponses aux questions du formulaire qui correspond au minimum aux informations demandées à l'annexe I du Protocole. Le notifiant se conformera toujours au cadre règlementaire national du Burkina Faso.
La prise de décision est faite après l'évaluation des risques conformément à l'article 15 du Protocole. Le coût de l'évaluation des risques est toujours pris en charge par l'auteur de la notification
La procédure de prise de décision est conforme à l'article 10 du Protocole à la différence que la notification de la décision doit intervenir dans les 150 jours à compter de la date de l'accusé de réception.
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
47. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
This question is relevant to indicator 1.1.2 of the Strategic Plan
  • Yes
48. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • Yes
49. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • Yes
50. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
This question is relevant to indicator 1.1.2 of the Strategic Plan
  • Yes
51. Has your country indicated its needs for financial and technical assistance and capacity-building in respect of LMOs-FFP?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • No
52. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
58. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP
FR
Le Burkina Faso n'a pas de loi spécifique sur les organismes vivants modifiés destinés à
être utilisés directement pour l'alimentation humaine ou animale, ou à être transformés. Cependant, cet aspect est pris en compte dans la loi et les règles nationales en matière de biosécurité.
Article 12 – Review of decision
59. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • Yes
60. Has your country ever received a request for a review of a decision?
  • No
61. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
62. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
66. Here you may provide further details on the implementation of Article 12 in your country
FR
Tout notifiant qui s'estime lésé par une décision peut, dans un délai de soixante jours, à partir de la date de réception de la notification de décision, exercer un recours contre la décision administrative conformément aux textes en vigueur.
Article 13 – Simplified procedure
67. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
68. Has your country ever applied the simplified procedure?
  • No
70. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
71. Here you may provide further details on the implementation of Article 13 in your country
FR
La loi dispose que si l'autorité compétente considère qu'il n'y a pas de risques significatifs pour la santé humaine et animale, la diversité biologique ou l'environnement, elle peut mettre en œuvre une procédure simplifiée définie par voie réglementaire.
Article 14 – Bilateral, regional and multilateral agreements and arrangements
72. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • Yes
73. If you answered Yes to question 72, how many LMO-related collaborative bilateral/multilateral arrangements has your country established with other Parties/non-Parties?
This question is relevant to indicator 1.2.8 of the Strategic Plan
  • One or more
74. If you answered Yes to question 72, has your country informed the Parties through the BCH of the agreements or arrangements?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • No
75. If you answered Yes to question 72, please provide a brief description of the scope and objective of the agreements or arrangements entered into
FR
Il s'agit d'un règlement communautaire qui concerne les OVM et leurs produits dérivés. C'est un cadre juridique et institutionnel pour prévenir réduire ou éliminer les risques potentiels liés à l'utilisation des biotechnologies modernes et des produits qui en sont issus. A cet effet :
a)  il définit les mesures de prévention et les procédures d'évaluation et de gestion des risques liés à l'utilisation des biotechnologies modernes et des produits qui en sont issus ;
b)  il détermine les principes et règles de responsabilité et de  réparation des dommages résultant de l'utilisation des OVM et produits dérivés;
c)  il institue les organes et mécanismes pour une approche  concertée de la prévention et de la gestion des risques biotechnologiques
76. Here you may provide further details on the implementation of Article 14 in your country
FR
Une réglementation régionale a été adoptée par les huit (8) pays de l'Union économique et monétaire ouest africaine (UEMOA) dont le Burkina Faso fait partie. Le document final n'est pas encore disponible. Ce document devrait par la suite être adopté par les quinze (15) pays de la Communauté économique des Etats de l'Afrique de l'ouest (CEDEAO) qui incluent ceux de l'UEMOA
Articles 15 & 16 – Risk Assessment and Risk Management
77. Has your country established a national framework for conducting risk assessments prior to taking decisions regarding LMOs?
  • Yes
78. If you answered Yes to question 77, does this framework include procedures for identifying and/or training national experts to conduct risk assessments?
  • Yes
79. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
This question is relevant to indicator 2.2.3 of the Strategic Plan
a) Risk assessment:
  • 10 or more
b) Management / Control:
  • 10 or more
c) Monitoring:
  • 10 or more
80. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • No
81. Is your country using the "Manual on Risk Assessment of LMOs" (developed by CBD Secretariat) for training in risk assessment?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • No
82. Is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • Yes
83. Are the currently available training materials or technical guidance on risk assessment and/or risk management of LMOs sufficient?
This question is relevant to indicator 2.2.6 of the Strategic Plan
  • No
84. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
This question is relevant to indicators 1.4.2 and 1.6.3 of the Strategic Plan
a) Detect:
  • Yes
b) Identify:
  • No
c) Assess:
  • No
d) Monitor:
  • No
85. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?
This question is relevant to indicators 1.3.1 of the Strategic Plan
a) Risk assessment:
  • Yes
b) Risk management:
  • Yes
86. Is your country using the "Guidance on Risk Assessment of LMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?
This question is relevant to indicator 2.2.5 of the Strategic Plan
  • No
87. Has your country adopted any common approaches to risk assessment with other countries?
This question is relevant to indicator 1.3.2 of the Strategic Plan
  • Yes
88. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
This question is relevant to indicator 1.4.1 of the Strategic Plan
  • No
89. Has your country ever conducted a risk assessment of an LMO including any type of risk assessment of LMOs, e.g. for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?
This question is relevant to indicator 1.3.3 of the Strategic Plan
  • Yes
90. If you answered Yes to question 89, please indicate the scope of the risk assessments (select all that apply):
  • Commercial production
  • Field trial
  • LMOs for Contained use
91. If you answered Yes to question 89, were the summary reports of the risk assessments submitted to the BCH?
This question is relevant to indicator 3.1.5 of the Strategic Plan
  • In some cases only
92. If you answered Yes to question 89, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs for direct use as food, feed, or for processing?
  • Yes, always
93. If you answered Yes to question 89, how many risk assessments were conducted in the current reporting period?
  • More than 10
94. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • Yes
95. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • Yes
96. Does your country have the infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?
This question is relevant to indicator 2.2.4 of the Strategic Plan
  • Yes
97. Here you may provide further details on the implementation of Articles 15 and 16 in your country
FR
Des experts sont commis à l'évaluation des risques. Ils ont suivi des formations. Cependant, des besoins en renforcement de capacité subsistent.
Selon la loi du Burkina Faso, l'utilisateur, avant toute utilisation d'OGM a la responsabilité de proposer des mesures de gestion des risques proportionnelles aux risques réels et potentiels inhérents à l'utilisation et à la dissémination dudit OGM. Ces mesures doivent être validées.
Article 17 – Unintentional transboundary movements and emergency measures
98. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • Yes
99. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • Yes
100. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released?
This question is relevant to indicator 1.8.3 of the Strategic Plan
  • No
101. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
105. Here you may provide further details on the implementation of Article 17 in your country
FR
Dans le cas du Burkina Faso, des plans d'intervention d'urgence sont prévus avant tout mouvement transfrontière pour gérer les éventuels accidents.
Article 18 – Handling, transport, packaging and identification
106. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • Yes
107. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
This question is relevant to indicator 1.6.1 of the Strategic Plan
  • Yes
108. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
This question is relevant to indicator 1.6.1 of the Strategic Plan
  • Yes
109. If you answered Yes or Yes, to some extent to question(s) 107 and/or 108, what type of documentation does your country require for the identification of LMOs-FFP?
  • Existing types of documentation
110. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
This question is relevant to indicator 1.6.2 of the Strategic Plan
  • Yes
111. If you answered Yes or Yes, to some extent to question 110, what type of documentation does your country require for the identification of LMOs that are destined for contained?
  • Existing types of documentation
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
This question is relevant to indicator 1.6.2 of the Strategic Plan
  • Yes
113. If you answered Yes or Yes, to some extent to question 112, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?
  • Existing types of documentation
114. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?
This question is relevant to indicator 1.6.4 of the Strategic Plan
  • Yes
115. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • Yes
116. How many customs officers in your country have received training in the identification of LMOs?
This question is relevant to indicator 2.3.1 of the Strategic Plan
  • 50 or more
117. Has your country established procedures for the sampling and detection of LMOs?
  • Yes
118. How many laboratory personnel in your country have received training in detection of LMOs?
This question is relevant to indicator 2.3.1 of the Strategic Plan
  • 10 or more
119. Does your country have reliable access to laboratory facilities for the detection of LMOs?
This question is relevant to indicator 2.3.2 of the Strategic Plan
  • Yes
120. How many laboratories in your country are certified for LMO detection?
This question is relevant to indicator 2.3.3 of the Strategic Plan
  • None
122. Here you may provide further details on the implementation of Article 18 in your country:
FR
Toute manipulation d'OGM doit faire l'objet d'une autorisation préalable de l'autorité compétente.
Des mesures adéquates doivent être prises par l'utilisateur en matière de transport afin d'éviter toute dissémination dans l'environnement. Un texte spécifique règlemente le transport des OGM.
Tout OGM importé destiné à la diffusion intentionnelle ou à la commercialisation sur le territoire national est emballé et étiqueté de manière indélébile et infalsifiable afin d'éviter les risques sur l'environnement et la santé humaine et animale. L'étiquette doit porter la mention "produit à base d'organismes génétiquement modifiés" ou "contient des organismes génétiquement modifiés".
Le terme préposé de douane  dans notre situation s'étend à tous les agents intervenant aux frontières sur le contrôle des produits: douaniers, agents phytosanitaires, agents d'élevage, des eaux et forêts et la police scientifique
A la question n°116, nous avons considéré le nombre de préposés ayant recu une formation en détection et non en identification des OVM tandis qu'à la question n°118, il s'agit d'employés de laboratoire formés en identification des OVM et non en détection des OVMs
Article 19 – Competent National Authorities and National Focal Points
123. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
  • Not applicable
124. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • Yes
125. Here you may provide further details on the implementation of Article 19 in your country
FR
La même entité (Agence nationale de biosécurité) assure les fonctions d'autorité nationale compétente et de correspondant national.
L'autorité compétente a acquis de part ses statuts une autonomie administrative et de gestion
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
126. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
This question is relevant to indicator 3.1.5 of the Strategic Plan
a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available but only partially available in the BCH
b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information available but only partially available in the BCH
c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information not available
d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available but only partially available in the BCH
f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information not available
g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information available but not in the BCH
j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information not available
k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information not available
l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information not available
m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information not available
n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information available but not in the BCH
127. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • No
128. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • No
129. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • Yes, in some cases
130. Has your country experienced difficulties accessing or using the BCH?
This question is relevant to indicator 4.1.8 of the Strategic Plan
  • No
131. Is the information submitted by your country to the BCH complete and up-to date?
  • No
132. Please indicate the number of regional, national and international events organized in relation to biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years:
This question is relevant to indicator 4.3.1 of the Strategic Plan
  • 25 or more
133. Please indicate the number of biosafety related publications that has been made available in your country in the last year:
This question is relevant to indicator 4.3.2 of the Strategic Plan
  • 10 or more
134. If biosafety related publications were made available (see question above), please indicate which modalities were preferred:
This question is relevant to indicator 4.3.2 of the Strategic Plan
  • National website
  • Presse écrite publique et privée
135. Here you may provide further details on the implementation of Article 20 in your country
FR
pour la question n°133, les publications parues entre octobre 2014 et septembre 2015 ont été prises en compte
Article 21 – Confidential information
136. Has your country established procedures to protect confidential information received under the Protocol?
  • Yes
137. Does your country allow the notifier to identify information that is to be treated as confidential?
  • Yes, always
138. Here you may provide further details on the implementation of Article 21 in your country
FR
La possibilité est donnée à l'auteur de la notification d'indiquer les informations confidentielles et lorsque ces dernières sont réellement jugées telles quelles, obligation est faite de les traiter en conséquence.
Article 22 – Capacity-building
139. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?
This question is relevant to indicator 1.2.6 and 3.1.8 of the Strategic Plan
  • No
140. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes, to some extent
Here you may provide further details
FR
participations à des formations organisées par des institutions régionales ou internationales (union UEMOA, ICGEB, ABNE, CORAF etc.)
141. If you answered Yes to question 140, how were these resources made available?
  • Bilateral channels
142. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
143. If you answered Yes to question 142, how were these resources made available?
  • Regional channels
144. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • Yes
145. If you answered Yes to question 144, how would you characterize the process?
Please add further details about your experience in accessing GEF funds under question 157.
  • Difficult
146. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Building Capacity for Effective Participation in the BCH (Phase I)
  • Building Capacity for Effective Participation in the BCH (Phase II)
  • Building Capacity for Effective Participation in the BCH (Phase III)
147. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
148. If you answered Yes to question 147, in which of the following areas were these activities undertaken?
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Identification of LMOs, including their detection
  • suivi post-liberation des OVM
149. During the current reporting period, has your country carried out a capacity-building needs assessment?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • Yes
150. If you answered Yes to question 149, has this information been submitted to the BCH?
This question is relevant to indicator 1.2.1 of the Strategic Plan
  • No
151. Does your country still have capacity-building needs?
This question is relevant to indicator 1.2.7 of the Strategic Plan
  • Yes
152. If you answered Yes to question 151, indicate which of the following areas still need capacity-building.
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
153. Has your country developed a capacity-building strategy or action plan?
This question is relevant to indicator 1.2.2 of the Strategic Plan
  • No
154. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?
This question is relevant to indicator 1.2.4 of the Strategic Plan
  • No
155. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?
This question is relevant to indicator 1.2.3 of the Strategic Plan
  • 1 per year or more
156. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • No
157. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds
FR
Le processus est long, fastidieux et pas toujours aisée à maîtriser.
UEMOA: union économique et monétaire ouest africaine;  ICGEB :International Centre for Genetic Engineering and Biotechnology; ABNE: African biosafety network of expertise, CORAF : conseil ouest et centre africain pour la recherche et le développement agricoles etc.)
Article 23 – Public awareness and participation
158. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes
159. Has your country designed and/or implemented an outreach/communication strategy on biosafety?
This question is relevant to indicator 5.3.2 of the Strategic Plan
  • Yes
160. Does your country have any awareness and outreach programmes on biosafety?
This question is relevant to indicator 5.3.1 of the Strategic Plan
  • Yes
161. If you answered Yes to question 160, please indicate what entity is responsible for carrying out the programmes and/or services and at which level the programmes take place (e.g. local, national, etc.):
This question is relevant to indicator 5.3.1 of the Strategic Plan
FR
L'Agence nationale de biosecurite, l'observatoire national de biosécurité et le forum ouvert sur les biotechnologies agricoles en Afrique (OFAB) ont la charge d'éxécuter en collaboration avec des personnes ressources les programmes en matière de sensibilisation et de diffusion sur la prévention des risques biotechnologiques.  Il s'agit d'un programme national qui est aussi exécuté au niveau local (dans les régions).
162. Has your country established a biosafety website searchable archives, national resource centres or sections in existing national libraries dedicated to biosafety educational materials?
This question is relevant to indicators 2.5.3 and 5.3.3 of the Strategic Plan
  • No
163. How many collaborative initiatives (including joint activities) on the Cartagena Protocol and other Conventions and processes has your government established in the last 4 years?
This question is relevant to indicator 5.2.1 of the Strategic Plan
  • One or more
164. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • Yes, to some extent
Here you may provide further details
FR
Dans le processus de prise de décision, il est prévu une information du public
165. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
This question is relevant to indicator 2.5.1 of the Strategic Plan
  • Yes, to some extent
Here you may provide further details
FR
La loi dispose que le public soit consulté pour les OVM devant être introduits dans l'environnement
166. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
This question is relevant to indicator 2.5.1 of the Strategic Plan
  • Yes
167. Has your country informed the public about existing modalities for public participation in the decision-making process regarding living modified organisms?
This question is relevant to indicator 2.5.2 of the Strategic Plan
  • No
170. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • Yes
171. How many academic institutions in your country are offering biosafety education and training courses and programmes?
This question is relevant to indicator 2.7.1 of the Strategic Plan
  • One or more
172. Please indicate the number of educational materials and/or online modules on biosafety that are available and accessible to the public in your country:
This question is relevant to indicators 2.7.2 and 5.3.4 of the Strategic Plan
  • None
173. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes
174. If you answered Yes to question 173, has your country cooperated with other States and international bodies?
  • Yes
175. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • Not applicable
176. Here you may provide further details on the implementation of Article 23 in your country
FR
L'information du public se fait par voie de presse (conférences, radios, télévisions, journaux) lorsqu'une décision est prise ou lorsque des préoccupations sont soulevées par les populations. Il en est de même des informations fournies par le Gouvernement à des groupes spécifiques tels que l'Assemblée nationale ou le Conseil économique et social.
Pour la participation du public, la loi prévoit cette disposition mais sa mise en œuvre reste encore assez complexe.
Dès que cela  est possible, l'adresse du CEPRB est communiquée au public  (exemple: sur les dépliants produits) et dans certains cas, son utilisation est expliqué (lors des séances de sensibilisation et d'information du public).
Article 24 – Non-Parties
177. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
178. Has your country ever imported LMOs from a non-Party?
  • Yes
179. Has your country ever exported LMOs to a non-Party?
  • No
180. If you answered Yes to questions 178 or 179, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?
  • Yes
181. If you answered Yes to questions 178 or 179, was information about these transboundary movements submitted to the BCH?
  • In some cases only
Article 25 – Illegal transboundary movements
184. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • Yes
185. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • Yes
186. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
If you replied Never to question 186 please go to question 191
  • Never
191. Here you may provide further details on the implementation of Article 25 in your country
FR
Les agents aux frontières (douaniers, agents phytosanitaires, agents d'élevage, agents des eaux et forêts, de la police scientifique)  et certains agents dans les écoles de formation sont pris en compte dans un programme national de formation théorique et d'utilisation pratique de kits de détection des OGM
Par ailleurs, les mouvements transfrontières illicites sont sanctionnés par la loi. 
Article 26 – Socio-economic considerations
192. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making?
This question is relevant to indicator 1.7.2 of the Strategic Plan
  • Yes
193. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • Not applicable
194. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations?
This question is relevant to indicator 1.7.1 of the Strategic Plan
  • One or more
195. What is your country's experience, if any, in taking socio-economic considerations into account in LMO decision making? Please give details:
This question is relevant to indicator 1.7.3 of the Strategic Plan
FR
Les aspects socio-économiques ayant été effectivement pris en compte dans le processus de prise de décision lors de l'adoption et du renouvellement du coton Bt sont les suivants: (i) revenus additionnels par rapport au coton conventionnel; (ii) effet de la culture du coton Bt sur l'amélioration de la santé des producteurs par la réduction des pulvérisations; (iii) la réduction de la pénibilité du travail; (iv) la réduction de la pollution par les pesticides
196. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • No
197. Here you may provide further details on the implementation of Article 26 in your country
FR
Dans la loi du Burkina Faso, les considérations socio-économiques retenues sont beacoup plus larges lors de la prise de décision. La loi dispose que l'autorité nationale compétente ne peut délivrer une autorisation que si elle établit que l'OGM :
- profite au pays sans causer de risque dommageable pour la santé humaine, animale, la diversité biologique et l'environnement;
- participe au développement durable;
- ne nuit pas à l'environnement socio-économique
Article 27 – Liability and Redress
198. Has your country ratified or acceded to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • Yes
200. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?
This question is relevant to indicator 2.4.1 of the Strategic Plan
  • No
201. Does your country have administrative or legal instrument that provide for response measures for damage to biodiversity resulting from living modified organisms?
This question is relevant to indicators 1.5.2 and 2.4.2 of the Strategic Plan
  • Yes
202. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress
FR
Beaucoup de sensibilisations et d'information ont été menées sur le protocole additionnel de Nagoya-Kuala Lumpur et sur sa transcription dans la nouvelle loi nationale. Cette nouvelle loi a été largement ventilée et a fait l'objet de formations à l'endroit d'un large public.
Article 28 – Financial Mechanism and Resources
203. How much additional funding (in the equivalent of US dollars) has your country mobilized in the last four years to support implementation of the Biosafety Protocol, beyond the regular national budgetary allocation?
This question is relevant to indicator 1.2.5 of the Strategic Plan
  • 1,000,000 USD or more
Article 33 – Monitoring and reporting
204. Does your country have in place a monitoring and/or an enforcement system for the implementation of the Cartagena Protocol?
This question is relevant to indicator 3.1.6 of the Strategic Plan
a) Monitoring system:
  • Yes
b) Enforcement system:
  • Yes
205. Has your country submitted all the previous due National Reports?
  • Yes
Other information
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
FR
Un financement exceptionnel à travers la composante nationale du Programme régional de biosécurité en Afrique de l'ouest avait été libéré et utilisé ces dernières années. Ce financement est arrivé à terme. Il n'y a plus de  budget spécifique conséquent qui sera consacré à l'application du Protocole au niveau national. Cela représente le défi majeur et il est nécessaire de mettre en place une stratégie de mobilisation durable des ressources. Il est aussi nécessaire de poursuivre le renforcement des capacités techniques, scientifiques et institutionnelles.